JP5839362B2 - ホルモン変動の症状を治療または予防するための方法および組成物 - Google Patents

ホルモン変動の症状を治療または予防するための方法および組成物 Download PDF

Info

Publication number
JP5839362B2
JP5839362B2 JP2012556166A JP2012556166A JP5839362B2 JP 5839362 B2 JP5839362 B2 JP 5839362B2 JP 2012556166 A JP2012556166 A JP 2012556166A JP 2012556166 A JP2012556166 A JP 2012556166A JP 5839362 B2 JP5839362 B2 JP 5839362B2
Authority
JP
Japan
Prior art keywords
symptoms
pharmaceutical composition
dextromethorphan
hormonal
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012556166A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013521297A (ja
JP2013521297A5 (OSRAM
Inventor
ロイスター，ジュニア，ジョージ，イー．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FERVENT PHARMACEUTICALS LLC
Original Assignee
FERVENT PHARMACEUTICALS LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FERVENT PHARMACEUTICALS LLC filed Critical FERVENT PHARMACEUTICALS LLC
Publication of JP2013521297A publication Critical patent/JP2013521297A/ja
Publication of JP2013521297A5 publication Critical patent/JP2013521297A5/ja
Application granted granted Critical
Publication of JP5839362B2 publication Critical patent/JP5839362B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2012556166A 2010-03-02 2011-03-01 ホルモン変動の症状を治療または予防するための方法および組成物 Active JP5839362B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30963810P 2010-03-02 2010-03-02
US61/309,638 2010-03-02
PCT/US2011/026650 WO2011109367A2 (en) 2010-03-02 2011-03-01 Methods and compositions for treating or preventing symptoms of hormonal variations

Publications (3)

Publication Number Publication Date
JP2013521297A JP2013521297A (ja) 2013-06-10
JP2013521297A5 JP2013521297A5 (OSRAM) 2014-05-15
JP5839362B2 true JP5839362B2 (ja) 2016-01-06

Family

ID=44531862

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012556166A Active JP5839362B2 (ja) 2010-03-02 2011-03-01 ホルモン変動の症状を治療または予防するための方法および組成物

Country Status (12)

Country Link
US (1) US20110218213A1 (OSRAM)
EP (1) EP2542241B1 (OSRAM)
JP (1) JP5839362B2 (OSRAM)
CN (1) CN102858343B (OSRAM)
AU (3) AU2011223807B2 (OSRAM)
BR (1) BR112012022052B1 (OSRAM)
CA (1) CA2828041C (OSRAM)
EA (1) EA027350B1 (OSRAM)
ES (1) ES2574210T3 (OSRAM)
IL (2) IL221706A (OSRAM)
PL (1) PL2542241T3 (OSRAM)
WO (1) WO2011109367A2 (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9616123B1 (en) * 2012-03-05 2017-04-11 Robert L. Knobler Method and compound for treatment of menopausal symptoms
SG11201708162UA (en) * 2015-04-07 2017-11-29 Meiji Co Ltd Hot flash-suppressing agent
WO2019094596A1 (en) 2017-11-09 2019-05-16 The Trustees Of Columbia University In The City Of New York Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders
US11491120B2 (en) 2017-11-09 2022-11-08 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders in females
WO2020219270A1 (en) * 2019-04-22 2020-10-29 Knobler Robert L Non-hormonal treatment of hot flashes
WO2021108801A2 (en) * 2019-11-15 2021-06-03 Consegna Pharma, Inc. Long acting nmda antagonists

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5321012A (en) * 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
CA2115792C (en) * 1993-03-05 2005-11-01 David J. Mayer Method for the treatment of pain
EP0729353B2 (en) * 1993-11-19 2012-09-12 Alkermes, Inc. Preparation of biodegradable microparticles containing a biologically active agent
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
WO2001007037A1 (en) * 1999-07-22 2001-02-01 University Of Rochester Method of treating symptoms of hormonal variation, including hot flashes
US20040002482A1 (en) * 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
US6569471B2 (en) * 2000-09-01 2003-05-27 Natumin Pharma Ab Method for the treatment of symptoms related to normal hormonal variations in women
US20050129783A1 (en) * 2001-04-19 2005-06-16 Mccleary Edward L. Composition and method for treatment of neurophysiological conditions and maintenance of neurophysiological health
WO2003037334A1 (en) * 2001-10-31 2003-05-08 Merck & Co., Inc. Method for treating or preventing symptoms of hormonal variation including hot flashes
UA81423C2 (en) * 2002-08-15 2008-01-10 PRODUCT CONTAINING SRI AND AGONIST OF THE 5HT2a RECEPTOR FOR TREATMENT OF THERMOREGULATORY DYSFUNCTION
HUP0303313A2 (hu) * 2003-10-09 2005-07-28 Richter Gedeon Vegyészeti Gyár Rt. Transzdermális gyógyszerkészítmények
US7855195B2 (en) * 2003-12-02 2010-12-21 Pharmaneuroboost N.V. Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
BRPI0510942A (pt) * 2004-05-11 2007-07-17 Pfizer Prod Inc combinação de antipsicóticos atìpicos e antagonistas do receptor 5-ht1b
CA2569411A1 (en) * 2004-06-04 2005-12-22 Mood Management Sciences, Llc Methods and compositions for treating mood disorder
US20060122127A1 (en) * 2004-11-17 2006-06-08 Cypress Bioscience, Inc. Methods for reducing the side effects associated with mirtzapine treatment
CA2614244A1 (en) * 2005-07-06 2007-01-11 Sepracor Inc. Combinations of eszopiclone and an antidepressant
WO2007070779A2 (en) * 2005-12-13 2007-06-21 Trinity Laboratories, Inc. A method to treat premature ejaculation in humans
MX2008009947A (es) * 2006-02-03 2008-10-20 Avanir Pharmaceuticals Composiciones farmaceuticas que comprenden dextrometorfano y quinidina para el tratamiento de depresion, ansiedad y trastornos neurodegenerativos.
US7645750B2 (en) * 2006-12-13 2010-01-12 Yung Shin Pharmaceutical Ind. Co., Ltd. Method of treating symptoms of hormonal variations
EP2134330B1 (en) * 2007-03-19 2013-05-08 Acadia Pharmaceuticals Inc. Combinations of 5-ht2a inverse agonists and antagonists with antipsychotics
CN102223893B (zh) * 2008-07-22 2014-07-16 曼诺吉尼克斯公司 治疗与绝经、激素改变和关节炎相关的症状的组合物和方法

Also Published As

Publication number Publication date
BR112012022052B1 (pt) 2021-06-29
EP2542241A2 (en) 2013-01-09
ES2574210T3 (es) 2016-06-15
EP2542241B1 (en) 2016-04-27
WO2011109367A4 (en) 2012-02-23
BR112012022052A2 (pt) 2020-07-07
EP2542241A4 (en) 2013-11-06
WO2011109367A3 (en) 2011-12-29
CA2828041C (en) 2018-04-17
IL253853A0 (en) 2017-09-28
CN102858343A (zh) 2013-01-02
CA2828041A1 (en) 2011-09-09
PL2542241T3 (pl) 2016-12-30
JP2013521297A (ja) 2013-06-10
WO2011109367A2 (en) 2011-09-09
AU2018205147A1 (en) 2018-08-02
IL221706A (en) 2017-08-31
AU2016213776A1 (en) 2016-09-01
EA201290851A1 (ru) 2013-04-30
CN102858343B (zh) 2015-11-25
AU2011223807B2 (en) 2016-05-12
AU2011223807A1 (en) 2012-10-18
AU2016213776B2 (en) 2018-04-12
EA027350B1 (ru) 2017-07-31
IL253853B (en) 2019-05-30
US20110218213A1 (en) 2011-09-08

Similar Documents

Publication Publication Date Title
US9457022B2 (en) Methods and compositions for treating or preventing symptoms of hormonal variations
US8420624B2 (en) Methods for treating or preventing symptoms of hormonal variations
AU2016213776B2 (en) Methods and compositions for treating or preventing symptoms of hormonal variations
Mom et al. Hot flushes in breast cancer patients
CN102697785B (zh) 治疗或防治激素变异症状的方法
CN1674880A (zh) 用于治疗体温调节机能障碍的5HT2a受体的激动作用
BG65677B1 (bg) Използване на дапоксетин, бързодействащ реактивен серотонинов инхибитор за лечение на сексуална дисфункция
US20040180879A1 (en) Novel method of treating vasomotor symptoms
WO2016106189A1 (en) Cis-clomiphene and its analogues as agents for androgen deprivation therapy
AU2014342520B2 (en) Novel treatments for attention and cognitive disorders, and for dementia associated with a neurodegenerative disorder
EP2089022A2 (en) Composition containing a mixture of antidepressants for treating premature ejaculation
US9339500B2 (en) Methods of treating vasomotor symptoms
CN116808004A (zh) 一种他莫昔芬乳腺透皮贴及其制备工艺
Buijs Long-term side effects of adjuvant breast cancer treatment
CN101189043A (zh) 肾上腺素能α2B拮抗剂用于治疗血管舒缩症状的应用

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A525

Effective date: 20121022

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140228

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140327

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150303

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150529

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150703

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150803

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20151006

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20151102

R150 Certificate of patent or registration of utility model

Ref document number: 5839362

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250